WZWenjun Zheng

Wenjun Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wenjun Zheng has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Xianghui Li

    Department of Dermatology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi 530021, China

    3 shared publications
  • Yuanyuan Chen

    Department of Dermatology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

    3 shared publications
  • Jiarong Lu

    Department of Dermatology and Venereology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China

    2 shared publications
  • Qiu-Ju Li

    Department of Dermatology, The First Affiliated Hospital of Guangxi Medical University

    2 shared publications
  • Qiu-Ju Wei

    Department of Dermatology, The First Affiliated Hospital of Guangxi Medical University

    2 shared publications
  • Qiuju Li

    Department of Dermatology and Venereology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China

    2 shared publications

Latest Publications

  • Open Access

    Topical sirolimus for the treatment of verrucous epidermal nevus associated with an HRAS mosaic mutation: a case report

    by Qiu-Ju Wei, Wan-Yan Xiang, Wen-Jun Zheng, Qiu-Ju Li

    Introduction: Verrucous epidermal nevus is a benign epidermal hamartoma associated with somatic mosaic mutations, which shows poor response to conventional therapies and has a high risk of recurrence. To date, there are no standardized treatment guidelines for this condition. In recent years, targeted treatments for specific gene mutations have provided new directions for the clinical management of this disease. Case report: We report a case of a 13-year-old child with verrucous epidermal nevus in whom genetic testing revealed an HRAS mosaic mutation. The child showed poor response to conventional treatments, including surgical excision, topical retinoic acid cream, and oral acitretin. However, after treatment with topical 0.5% (w/w) sirolimus ointment, the child’s skin lesions showed reduced area, thinning, improved pigmentation, and decreased roughness, and no local or systemic adverse reactions were observed during the 6-month treatment period. Conclusion: This case suggests that topical sirolimus may represent a potentially effective therapeutic option for patients with verrucous epidermal nevus who are refractory to conventional therapy.

  • ANKFN1 in skin fibroblasts may modulate mast cell activity and is associated with dupilumab response in atopic dermatitis

    by Qiu-Ju Wei, Jia-Rong Lu, Wan-Yan Xiang, Hai-Qi Liang, Si-Qi Zhang, Si-Yu Huang, Jun-Wen Peng, Ze-Feng Zhou, Qiu-Ju Li, Wen-Jun Zheng

    Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disease. Dupilumab is a new targeted drug used to treat moderate to severe AD. However, some patients with AD exhibit poor response to dupilumab treatment. This study aims to investigate the potential role and mechanisms of ANKFN1 in the development of resistance to dupilumab in AD. This study conducted a comprehensive analysis of bulk RNA, single-cell RNA (scRNA-seq), and spatial transcriptome sequencing data. A prospective cohort of 54 AD patients treated with dupilumab was analyzed. Based on the SCORAD score, we measured whether the AD patients responded to 16 weeks of dupilumab treatment. By analyzing differentially expressed genes between the pre-treatment response group and the resistant group, drug resistance-associated genes were identified and externally validated in an independent dataset. Subsequently, biological function enrichment analysis, immune cells assessment, scRNA-seq analysis, and spatial transcriptomics were employed to investigate ANKFN1's biological functions, cellular localization, and association with the immune microenvironment. Additionally, we constructed a ceRNA regulatory network. Four key genes ANKFN1, HTR3A, HLA-DQA1, and ALOX15B were identified, with ANKFN1 exhibiting the strongest predictive efficacy (AUC = 0.938) and showing significantly upregulated expression in the resistant group, a finding confirmed in the validation cohort. High ANKFN1 expression positively correlated with resting mast cell infiltration levels and negatively correlated with immune stimulatory factors, chemokines, and IL-4/IL-13 pathway receptors (IL4R, IL13RA1, IL13RA2), suggesting its association with an immunosuppressive microenvironment. scRNA-seq analysis revealed ANKFN1 was specifically overexpressed in fibroblasts, particularly within the COL6A5⁺ fibroblast subpopulation. Spatial transcriptomics analysis further validated this finding. The ceRNA network suggested ANKFN1 may be regulated by the lncRNA NEAT1/miR-224 axis and transcription factors AR and GRHL2. ANKFN1 may be associated with dupilumab non-response and warrants further validation.


  • Open Access

    Clinical characteristics of Netherton syndrome and exploration of targeted biologic therapy: two case reports

    by Wanyan Xiang, Chengxiang Lian, Jiarong Lu, Wenjun Zheng, Qiuju Li

    Background: Netherton syndrome (NS) is a rare, autosomal recessive disease resulting from a mutation in the pathogenic variants in the Kazal type 5 (SPINK5) gene. In recent years, the targeted treatment of biological agents has increasingly emerged as a focal point of research.Case reports: We reported a 4-month-old child and 19-year-old female, both presenting with symptoms including erythema, scaling, and recurring episodes. Subsequently, genetic testing identified a defective SPINK5 gene, leading to a diagnosis of NS. The child received treatment with dupilumab, while the 19-year-old woman alternated between using dupilumab and secukinumab. Both patients had swift and enduring enhancement of skin lesions during the follow-up period.Conclusion: NS is an uncommon and frequently misdiagnosed hereditary dermatological disease. The management strategies for this condition are diverse, and no consensus exists. We implemented various biologic regimens for distinct patients, all demonstrating favorable outcomes and satisfactory tolerance. Besides, monitoring and evaluating the long-term safety of biologics in combination is essential.


  • Open Access

    Non-Tuberculous Mycobacterial Infections of the Skin and Soft Tissue in a Chinese Population: A Retrospective Analysis of 15 Cases

    by Hongyu Tao, Wenjun Zheng

    Background: Non-tuberculous mycobacteria (NTM) skin and soft tissue infections (SSTIs) are increasingly recognized but underdiagnosed in China. Methods: This retrospective study analyzed 15 confirmed cases of NTM SSTIs treated at a southern Chinese hospital from 2012 to 2022. Clinical data, including demographics, clinical presentations, comorbidities, diagnostic methods, treatment regimens, and outcomes, were collected and analyzed. Diagnostic efficacy of conventional culture and metagenomic next-generation sequencing (mNGS) was compared. Results: The median age of patients was 57 years, and 66.7% were farmers. Pathogens identified included Mycobacterium abscessus (20.0%), M. marinum (13.3%), and rapidly growing mycobacteria (13.3%). Immunocompromised states, such as anti-interferon-gamma autoantibody positivity, were present in 40.0%. mNGS demonstrated superior diagnostic performance, achieving a detection rate of 86.7% (13/15 cases), compared to 26.7% for culture. Treatment regimens, including clarithromycin, rifampin, ethambutol, and moxifloxacin, lasted 1– 24 months. Outcomes showed cure in 8 patients (53.3%), improvement in 6 (40.0%), and 1 lost to follow-up. Conclusion: NTM SSTIs present significant diagnostic and therapeutic challenges, with clinical variability and frequent association with immunocompromised states. M. abscessus, M. marinum, and M. avium were the predominant pathogens. mNGS improves detection but still should complement culture. Precise pathogen identification and tailored therapy are essential for achieving optimal outcomes, and further studies are needed to refine diagnostics and treatment strategies.


  • Open Access

    The role and prospects of skin microbiota in dermatosis

    by Yuanyuan Chen, Zhijian Yao, Zhuren Ruan, Gao Wei, Wenjun Zheng, Xianghui Li

    The skin microbiota is crucial in defending against toxic, solar, and pathogenic assaults, yet it can also precipitate dermatosis when its equilibrium is disrupted. The composition and distribution of various microorganisms within the skin maintain a dynamic balance, modulating the barrier function and the immune system, thereby constituting the skin microbiota. This microbiota not only offers new insights into pathological microbe-host interactions and associated dermatoses but also inspires innovative therapeutic strategies that promise high efficacy and reduced symptomatology. In this review, we synthesize recent advancements in the field of skin microbiota, focusing on its relationship with dermatosis and the application of microbiota-based therapies in skin diseases. Our aim is to scrutinize the current understanding of the skin microbiota’s role, ranging from a protective barrier to a causative agent of dermatosis.


  • Open Access

    Full‐active pharmaceutical ingredient nanosensitizer for augmented photoimmunotherapy by synergistic mitochondria targeting and immunogenic death inducing

    by Xianghui Li, Haoran Wang, Zhiyan Li, Song Liu, Yuanyuan Chen, Zhuren Ruan, Zhijian Yao, Gao Wei, Cunwei Cao, Wenjun Zheng, et al.

    The precise and effective activation of the immune response is crucial in promising therapy curing cancer. Photoimmunotherapy (PIT) is an emerging strategy for precise regulation and highly spatiotemporal selectivity. However, this approach faces a significant challenge due to the off‐target effect and the immunosuppressive microenvironment. To address this challenge, a nanoscale full‐active pharmaceutical ingredient (API) photo‐immune stimulator was developed. This formulation overcomes the limitations of PIT by strengthening the ability to penetrate tumors deeply and inducing precise and potent mitochondria‐targeted dual‐mode photodynamic therapy and photothermal therapy. Along with inhibiting overexpressed Hsp90, this nanosensitizer in turn improves the immunosuppressive microenvironment. Ultimately, this mitochondria‐targeted PIT demonstrated potent antitumor efficacy, achieving a remarkable inhibition rate of ≥95% for both established primary tumors and distant abscopal tumors. In conclusion, this novel self‐delivery full‐API nanosystem enhances the efficacy of phototherapy and reprograms the immunosuppressive microenvironment, thereby holding great promise in the development of precise and effective immunotherapy.


  • Open Access

    Prediction of immune infiltration and prognosis for patients with gastric cancer based on the immune-related genes signature

    by Xianghui Li, Yuanyuan Chen, Yuxiang Dong, Zhongjin Ma, Wenjun Zheng, Youkun Lin